People: ZIOPHARM Oncology Inc (ZIOP.W)

Summary

Name	Age	Since	Current Position
Jonathan Lewis	53	2005	Chief Executive Officer, Director
Jason Amello	43	2012	Chief Financial Officer, Executive Vice President
Caesar Belbel	52	2011	Executive Vice President, Chief Legal Officer, Secretary
Murray Brennan	72	2010	Non-Executive Lead Independent Director
Randal Kirk	58	2011	Director
James Cannon	73	2005	Independent Director
Wyche Fowler	71	2005	Independent Director
Timothy McInerney	51	2005	Independent Director
Michael Weiser	49	2005	Independent Director

» Insider Trading

Biographies

Name	Description
Jonathan Lewis	Dr. Jonathan Lewis, M.D., Ph.D., is Chief Executive Officer, Director of ZIOPHARM Onclology, Inc. Dr. Lewis previously served as Chief Executive Officer and a director of ZIOPHARM, Inc. since January 2004. He served as Chief Medical Officer and Chairman of the Medical Board at Antigenics, Inc. from June 2000 until November 2003. From July 1994 until June 2001, Dr. Lewis served as Professor of Surgery and Medicine at Memorial Sloan-Kettering Cancer Center. He has been actively involved in translational and clinical research in cancer, and is widely recognized by patient advocacy groups. He has received numerous honors and awards in medicine and science, including the American Society of Clinical Oncology young investigator award, the Yale University Ohse award, and the Royal College of Surgeons Trubshaw Medal. He serves as a director on the board of directors of the Police Organization Providing Peer Assistance of the New York City Police Department, the Medical Advisory Board of the Sarcoma Foundation of America and as Chairman of the board of directors of the Hope Funds for Cancer Research. Dr. Lewis previously served as a director of Delcath Systems, Inc., a development stage, specialty pharmaceutical and medical device company focused on oncology, from June 2007 to December 2008. Dr. Lewis holds a MB.B.Ch. from Witwatersrand University School of Medicine (Johannesburg, South Africa) and a Ph.D. in molecular biology from Witwatersrand and Yale University School of Medicine.
Jason Amello	Mr. Jason A. Amello has been appointed as Chief Financial Officer, Executive Vice President of ZIOPHARM Oncology, Inc., effective May 8, 2012. Mr. Amello has over 20 years of leadership experience guiding strategic business growth and operational performance through roles covering finance, accounting, corporate and capital markets strategies and mergers and acquisitions. For 11 years, Mr. Amello served in various roles of increasing responsibility at Genzyme Corporation, a Sanofi company, most recently as Senior Vice President, Corporate Controller and Chief Accounting Officer. While at Genzyme, Mr. Amello served as one of the key executives in connection with the company’s mergers and acquisition and corporate partnering activities, which contributed to Genzyme’s 5-fold growth over 10 years. Prior to Genzyme, Mr. Amello spent 10 years in the business advisory and assurance practice of Deloitte & Touche, serving in various roles of increasing responsibility through Senior Manager. Mr. Amello holds a B.S. degree from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.
Caesar Belbel	Mr. Caesar J. Belbel is Executive Vice President, Chief Legal Officer, Secretary of ZIOPHARM Oncology Inc., with effect from 6 September 2011. From May 2003 to May 2011, he was Executive Vice President, Chief Legal Officer and Secretary of Clinical Data, Inc., a biopharmaceutical company that was acquired in April 2011 by Forest Laboratories, Inc. Mr. Belbel holds a B.A. from Columbia University and a J.D. from Boston College Law School.
Murray Brennan	Dr. Murray Brennan is Non-Executive Lead Independent Director of ZIOPHARM Oncology, Inc. Dr. Brennan, who currently serves as the Board of Directors’ non-executive Lead Director, has been a director of the Company since its September 2005 acquisition of ZIOPHARM, Inc. and previously served as a director of ZIOPHARM, Inc. since December 2004. Dr. Brennan is Emeritus Chairman of Memorial Sloan-Kettering’s Department of Surgery and previously served as Chairman since 1985. Dr. Brennan is the Benno C. Schmidt Chair in Clinical Oncology at the Memorial Sloan Kettering Cancer Center, continues to operate at this institution and currently serves as its Vice President for International Programs. He actively lectures at institutions throughout the world and has authored or co-authored more than 1000 scientific papers. He previously served as Director of the American Board of Surgery, Chairman of the American College of Surgeons Commission on Cancer, President of the Society of Surgical Oncology, President of the American Surgical Association, President of the Society of Clinical Surgery and Vice President of the American College of Surgeons. Dr. Brennan is a member of the Institute of Medicine of The National Academy of Sciences. He is the recipient of numerous honors, honorary degrees and fellowships for his leadership role in surgery and oncology worldwide. Dr. Brennan serves as a non-executive Director on the Board of QSII (a medical information company) and as a member of its compensation committee. He also serves on the Board of the de Beaumont Foundation, a charitable foundation designed to support public health in the United States and elsewhere.
Randal Kirk	Mr. Randal J. Kirk is Director of ZIOPHARM Oncology Inc. Mr. Kirk is the Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm founded by Mr. Kirk. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (previously traded on NASDAQ prior to its acquisition by Shire plc in 2007) in 1996, and was President and Chief Executive Officer between October 2001 and April 2007. Mr. Kirk began his professional career in the private practice of law. Previously, Mr. Kirk served as a member of the Board of Directors of Scios, Inc. (previously traded on NASDAQ prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, was a member of the board of directors of Howe and Rustling, Inc., a registered investment advisory firm, from December 2001 to October 2006 and was a member of the Board of Directors of Clinical Data, Inc. (previously traded on NASDAQ prior to its acquisition by Forest Laboratories, Inc. in April 2011) from September 2002 to April 2011, and was Chairman of the Board from December 2004 to April 2011. Mr. Kirk currently serves in a number of additional capacities, including as a member of the Board of Directors of Halozyme Therapeutics, Inc. since May 2007; as Chairman of the Board of Directors of Intrexon Corporation since February 2008 and Chief Executive Officer since April 2009; and as Chairman of the Board of Directors of Cyntellect, Inc. since September 2008. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia.
James Cannon	Mr. James A. Cannon is Independent Director of ZIOPHARM Oncology, Inc. Previously he served as a Director of ZIOPHARM, Inc., since December 2004. Mr. Cannon is Vice Chairman, Chief Financial Officer and a member of the Board of Directors of BBDO Worldwide. In these capacities, he oversees the financial management of BBDO operations in 77 countries. Jim joined BBDO in 1967, was promoted to Chief Financial Officer of the agency in 1984, and was elected to its Board of Directors one year later. An integral member of the team that formed Omnicom via a unique three-agency merger of BBDO, DDB and Needham Harper & Steers, Jim became Comptroller of the new group (NYSE: OMC) and a member of its Board of Directors in 1986, a position he held through 2002. In 1987, he was appointed Director of Financial Operations of the Omnicom Group, serving in this capacity until early 1989 when he rejoined BBDO Worldwide as Executive Vice President and Chief Financial Officer. His return was concurrent with that of Allen Rosenshine who became Chairman and Chief Executive officer of BBDO after heading Omnicom. Jim was promoted to Vice Chairman of the agency in 1990. Jim is a graduate of Pace University and served in the US Marine Corps.
Wyche Fowler	Senator Wyche Fowler, Jr., J.D., is Independent Director of ZIOPHARM Oncology, Inc. Previously served as a Director of ZIOPHARM, Inc. since December 2004. Senator Fowler served for 16 years in the United States Congress. In the U.S. Senate he served as assistant floor leader, helping mold a bipartisan consensus for public policy issues. Senator Fowler was a member of the U.S. Senate Appropriations, Budget, Energy and Agriculture Committees. First elected to the U.S. House of Representatives, he was a member of the Ways and Means and Foreign Affairs Committees, as well as the Select Committee on Intelligence. President Clinton appointed Senator Fowler U.S. Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. On his return, the FBI awarded him its highest civilian honor, The Jefferson Cup, for his assistance in combating terrorism and for helping solve terrorism crimes against the U.S. military in Saudi Arabia. He was named Lion of Judah by the State of Israel for freeing Soviet Jew Yakov Gluzman. Senator Fowler is now engaged in an international business and law practice, and also serves as Chairman of the Board of the Middle East Institute, a non-profit foundation in Washington, DC. Senator Fowler also serves on the board of directors of Shubert Theaters, the Shubert Foundation, Brandywine Realty Trust and Keryx Biopharmaceuticals, Inc., a biopharmaceutical company. Senator Fowler holds an A.B. in English from Davidson College and a J.D. from Emory University School of Law.
Timothy McInerney	Mr. Timothy McInerney is Independent Director of ZIOPHARM Oncology, Inc. Previously served as a director of ZIOPHARM, Inc. since July 2005. In June of 2007, Mr. McInerney joined Riverbank Capital, which specializes in financing for the biotech and specialty pharmaceutical industry, as a Partner. From 1992 to March 2007, Mr. McInerney was a Managing Director of Paramount BioCapital, Inc. where he oversaw the overall distribution of Paramount’s private equity product. Prior to 1992, Mr. McInerney was a research analyst focusing on the biotechnology industry at Ladenburg, Thalman & Co. Prior to that, Mr. McInerney held equity sales positions at Bear Sterns & Co. and Shearson Lehman Brothers, Inc. Mr. McInerney also worked in sales and marketing for Bristol-Myers Squibb. He received his B.S. in pharmacy from St. John’s University at New York. He also completed a post-graduate residency at the New York University Medical Center in drug information systems. Mr. McInerney currently serves as Chairman of the board of directors of Insite Vision Inc., an opthalmologic product development company, Emisphere Technologies, Inc., a biopharmaceutical company, and Edgemont Pharmaceuticals, LLC, a pharmaceutical company, and previously served on the board of directors of Manhattan Pharmaceuticals, Inc. a biopharmaceutical company.
Michael Weiser	Dr. Michael Weiser, M. D., Ph.D., is Independent Director of the ZIOPHARM Oncology, Inc. Previously served as a director of ZIOPHARM, Inc. since its inception in September 2003. Dr. Weiser is currently founder and co-chairman of Actin Biomed, a New York-based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed in December 2006, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. In addition, Dr. Weiser has received awards for both academic and professional excellence and is published in both medical and scientific journals. Dr. Weiser is a member of The National Medical Honor Society, Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology and Association for Research in Vision and Ophthalmology. Dr. Weiser currently serves on the board of directors of Chelsea Therapeutics International and Emisphere Technologies, Inc., both biopharmaceutical companies, as well as on the board of directors of several privately held companies. Dr. Weiser previously served as a director of Hana Biosciences, Inc., Manhattan Pharmaceuticals, Inc. and Vioquest Pharmaceuticals, Inc. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont.

Basic Compensation

Name	Fiscal Year Total
Jonathan Lewis	1,066,330
Jason Amello	--
Caesar Belbel	937,327
Murray Brennan	--
Randal Kirk	--
James Cannon	--
Wyche Fowler	--
Timothy McInerney	--
Michael Weiser	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Jonathan Lewis	410,603	851,675
Jason Amello	0	0
Caesar Belbel	0	0
Murray Brennan	0	0
Randal Kirk	0	0
James Cannon	0	0
Wyche Fowler	0	0
Timothy McInerney	0	0
Michael Weiser	0	0

Insider Trading

Name	Shares Traded	Price
AMELLO JASON A	2,623	$1.65
BELBEL CAESAR J	5,400	$4.50
FOWLER WYCHE JR	17,546	$0.00
YOUSSOUFIAN HAGOP	6,919	$4.21
MCINERNEY TIMOTHY	17,546	$0.00
WEISER MICHAEL	1,904	$4.21
WEISER MICHAEL	17,546	$0.00
BELBEL CAESAR J	2,284	$4.21
CANNON JAMES ANTHONY	1,465	$4.21
KIRK RANDAL J	17,546	$0.00
CANNON JAMES ANTHONY	17,546	$0.00
LEWIS JONATHAN	14,715	$4.21
LEWIS JONATHAN	21,475	$4.16
KIRK RANDAL J	3,636,926	$0.00
YOUSSOUFIAN HAGOP	15,740	$6.06
WEISER MICHAEL	27,844	$5.02
MCINERNEY TIMOTHY	20,767	$3.93
MCINERNEY TIMOTHY	16,258	$5.02
WEISER MICHAEL	35,566	$3.93
AMELLO JASON A	25,000	$0.00
BELBEL CAESAR J	43,802	$0.00
KIRK RANDAL J	1,923,075	$5.20
LEWIS JONATHAN	21,475	$4.41
BAGLEY RICHARD E	7,908	$4.41
LEWIS JONATHAN	102,781	$0.00

» Full list on Insider Trading

People: ZIOPHARM Oncology Inc (ZIOP.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: